FDA declines to authorize fluvoxamine as a COVID-19 treatment


The Food and Drug Administration said Monday that it won’t authorize fluvoxamine, a generic treatment for obsessive-compulsive disorder, as a COVID-19 therapy. “The FDA has determined that the data are insufficient to conclude that fluvoxamine may be effective in the treatment of nonhospitalized patients with COVID-19 to prevent progression to severe disease and/or hospitalization,” the regulator said, citing the need to look at the totality of scientific data. A group of physicians led by the University of Minnesota’s Dr. David Boulware in late 2021 formally requested that the FDA authorize fluvoxamine as a COVID-19 treatment. “I’m disappointed that FDA holds generics to different standards as big pharma, in this case using different definition of endpoints of what is a [COVID-19-related] ‘hospitalization,'” Boulware tweeted Monday.

This article was originally published by Marketwatch.com. Read the original article here.

Previous articleOutside the Box: Fix these 3 things so federal and state governments can offer more targeted help during the next recession
Next articleMcDonald’s will exit Russia, starts process of selling business in the country


Please enter your comment!
Please enter your name here